| 0.2531 0.011 (4.59%) | 12-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Bionomics Limited is an Australian biopharmaceutical company operating at the clinical stage, dedicated to the discovery and advancement of innovative therapeutic compounds. Its research efforts primarily target central nervous system disorders and various cancers, with operations spanning Australia and the United States. A key experimental medicine in its portfolio is BNC210. This compound, which functions as a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, has successfully concluded Phase 2 trials for addressing social anxiety disorder and post-traumatic stress disorder. The company is also developing BNC375, a small molecule therapeutic aimed at improving cognitive function in patients suffering from Alzheimer's disease. Another asset, BNC101, a monoclonal antibody engineered to target cancer stem cells, has concluded its Phase 1 clinical assessment. Moreover, Bionomics is advancing BNC105, a vascular disrupting agent. This agent is currently in Phase 2 clinical trials for the treatment of refractory colorectal cancer and in Phase 1 trials for individuals with relapsed/refractory chronic lymphocytic leukemia. Further bolstering its capabilities, Bionomics Limited maintains a licensing agreement with the pharmaceutical giant Merck & Co., Inc. Established in 1996, the company maintains its corporate headquarters in Eastwood, Australia.
Thu, 24 Apr 2025
Bionomics (BNOX) Stock Price, News & Analysis - Stock Titan
Sun, 23 Mar 2025
Bionomics Ltd ADR (NASDAQ: BNOX) Share Price, BNOX Stock News, BNOX Share Price & Updates - Kalkine
Fri, 08 Nov 2024
Friday's after hours session: top gainers and losers - ChartMill
Wed, 23 Oct 2024
Bionomics to Present at the ThinkEquity Conference - GlobeNewswire
Mon, 14 Oct 2024
BNOX stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com UK
Mon, 30 Sep 2024
Bionomics Ltd (BNOX:UQ): Stock Price, Quote and News - BNN Bloomberg
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|